Edition:
United States

Grifols SA (GRFS.OQ)

GRFS.OQ on NASDAQ Stock Exchange Global Select Market

20.12USD
3:51pm EDT
Change (% chg)

$-0.18 (-0.89%)
Prev Close
$20.30
Open
$20.27
Day's High
$20.42
Day's Low
$20.12
Volume
95,554
Avg. Vol
145,940
52-wk High
$25.17
52-wk Low
$19.92

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  GRFS.OQ Industry Sector
P/E (TTM): -- 29.65 32.31
EPS (TTM): -- -- --
ROI: -- 13.36 12.97
ROE: -- 15.09 14.84

BRIEF-Grifols Concludes Experimental Phase Of Clinical Trial On Alzheimer

* SAYS CONCLUDES EXPERIMENTAL PHASE OF AMBAR, A CLINICAL TRIAL ON ALZHEIMER'S DISEASE

Mar 22 2018

BRIEF-Grifols To Buy German Pharmaceutical Company Haema For 220 Mln Euros

* SAYS REACHES DEAL WITH ATON GMBH TO BUY 100 PERCENT OF HAEMA AG FOR 220 MILLION EUROS ON A DEBT FREE BASIS ‍​ Source text for Eikon:

Mar 20 2018

Spanish stocks - Factors to watch on Wednesday

The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

Mar 14 2018

BRIEF-Grifols Announces New Agreement With Henry Schein To Distribute Normal Saline Solution In U.S.

* GRIFOLS - ANNOUNCES NEW AGREEMENT WITH HENRY SCHEIN TO DISTRIBUTE NORMAL SALINE SOLUTION IN THE U.S.

Mar 05 2018

Spanish stocks - Factors to watch on Wednesday

The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

Feb 28 2018

BRIEF-Grifols FY Net Profit Up At 662.7 Mln Euros

* FY NET SALES 4.32 BILLION EUROS VERSUS 4.05 BILLION EUROS YEAR AGO

Feb 28 2018

BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment

* GRIFOLS HYPERRAB® (RABIES IMMUNE GLOBULIN) 300 IU/ML RECEIVES FDA APPROVAL TO TREAT PATIENTS EXPOSED TO RABIES VIRUS INFECTION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 06 2018

BRIEF-Grifols Sees Positive Impact Of 90 Mln Euros In Q4 After Revaluation Of US Assets

* SEES POSITIVE NON-RECURRING IMPACT OF ABOUT 90 MILLION EUROS NET IN Q4 FROM US TAX REFORM AND REASSESSMENT OF ASSETS RELATED TO ARADIGM Source text for Eikon:

Jan 30 2018

BRIEF-Grifols Buys 51 Pct Of Medkeeper

* SAYS PURCHASE RESULT OF $98 MLN CAPITAL INCREASE IN MEDKEEPER

Jan 26 2018

BRIEF-Grifols Gets Loan With EIB For 85 Mln Euros

* GETS LONG-TERM LOAN WITH THE EUROPEAN INVESTMENT BANK (EIB) FOR 85 MILLION EUROS

Dec 05 2017

Earnings vs. Estimates

No consensus analysis data available.